ValuEngine upgraded shares of Evolent Health (NYSE:EVH) from a buy rating to a strong-buy rating in a report issued on Friday morning.
Other analysts have also issued research reports about the stock. TheStreet raised shares of Evolent Health from a d+ rating to a c- rating in a research report on Monday, June 4th. Cantor Fitzgerald reaffirmed a buy rating and set a $37.00 price target on shares of Evolent Health in a research report on Wednesday, September 12th. Zacks Investment Research raised shares of Evolent Health from a hold rating to a buy rating and set a $26.00 price target on the stock in a research report on Tuesday, July 10th. MED lifted their price target on shares of Evolent Health from $22.00 to $31.00 and gave the company an outperform rating in a research report on Monday, June 18th. Finally, KeyCorp lifted their price target on shares of Evolent Health from $24.00 to $26.00 and gave the company an overweight rating in a research report on Thursday, June 7th. One equities research analyst has rated the stock with a sell rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus target price of $28.67.
EVH stock opened at $26.90 on Friday. The company has a market cap of $2.06 billion, a PE ratio of -39.00 and a beta of 1.22. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.59 and a current ratio of 2.59. Evolent Health has a one year low of $10.30 and a one year high of $28.20.
Evolent Health (NYSE:EVH) last released its quarterly earnings results on Tuesday, August 7th. The technology company reported ($0.03) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $0.01. The firm had revenue of $144.51 million for the quarter, compared to analyst estimates of $141.90 million. Evolent Health had a negative net margin of 9.84% and a negative return on equity of 1.82%. analysts forecast that Evolent Health will post -0.35 earnings per share for the current year.
In related news, CEO Frank J. Williams sold 47,314 shares of Evolent Health stock in a transaction that occurred on Thursday, June 21st. The shares were sold at an average price of $24.00, for a total value of $1,135,536.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Thomas Peterson III sold 70,000 shares of Evolent Health stock in a transaction that occurred on Thursday, September 13th. The shares were sold at an average price of $27.50, for a total transaction of $1,925,000.00. The disclosure for this sale can be found here. Insiders sold a total of 529,641 shares of company stock valued at $12,434,610 in the last quarter. 4.82% of the stock is owned by insiders.
A number of institutional investors have recently bought and sold shares of EVH. Dimensional Fund Advisors LP increased its holdings in Evolent Health by 45.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,818,720 shares of the technology company’s stock valued at $59,335,000 after purchasing an additional 876,358 shares during the last quarter. Baillie Gifford & Co. acquired a new position in shares of Evolent Health in the second quarter worth $18,276,000. Chicago Capital LLC acquired a new position in shares of Evolent Health in the first quarter worth $12,254,000. Cortina Asset Management LLC grew its stake in shares of Evolent Health by 170.6% in the second quarter. Cortina Asset Management LLC now owns 1,240,945 shares of the technology company’s stock worth $26,122,000 after acquiring an additional 782,283 shares in the last quarter. Finally, Riverbridge Partners LLC grew its stake in shares of Evolent Health by 25.6% in the second quarter. Riverbridge Partners LLC now owns 3,536,179 shares of the technology company’s stock worth $74,437,000 after acquiring an additional 719,956 shares in the last quarter.
About Evolent Health
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.
Featured Article: Return on Equity (ROE)
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.